B+
Bull case
25%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
KLRS
Kalaris TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-25
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+59.2
Score
AI commentary
Cautious monitoring, consistent with the deterministic neutral prior and low coverage. The SEC-filed company release supports the clinical timetable and runway, but the packet provides no recent-news set, sufficient social coverage, verified analyst revisions or post-release price reaction. Zero-valued sentiment fields denote unavailable inputs, not observed neutral readings. [#SEC-8K-2026-08-11]
RankAlpha Sentiment Codex - 2026-10-25
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2027-06-30eventTH103 Phase 1b/2 preliminary dataHigh impact
Kalaris reported ongoing dosing in its neovascular AMD dose-finding study and anticipated preliminary data in the first half of 2027. Safety, efficacy and dose selection could materially change the thesis. The probability estimates timely disclosure, not clinical success. [#8-K-2026-08-11] [#SEC-8K-2026-08-11]
2027-10-01catalystRunway and financing riskHigh impact
Cash, equivalents and marketable securities declined from $118.0 million at year-end 2025 to $93.5 million at June 30, 2026. Management expected funding into the fourth quarter of 2027; delays or higher trial spending could accelerate financing needs. The probability is a subjective estimate of financing risk. [#SEC-8K-2026-08-11]
2027-12-31eventPotential Phase 3 initiationHigh impact
Kalaris said potential Phase 3 trials remained on track for initiation by year-end 2027. That plan depends on supportive earlier-stage data and execution; initiation is not assured. [#SEC-8K-2026-08-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-25 • Updated nightlySource: Internal modelMethodology